股本结构
单位：万股
| 公告日期 | 2026-08-11 | 2026-08-11 | 2026-05-12 | 2026-05-04 | 2026-05-12 | 2026-03-31 |
|---|---|---|---|---|---|---|
| 证券总股本 | 561.14 | 466.57 | 420.21 | 398.33 | 392.28 | 392.28 |
| 普通股本 | 561.14 | 466.57 | 420.21 | 398.33 | 392.28 | 392.28 |
| 优先股 | 未披露 | 0.03 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-10 | 2026-06-30 | 2026-05-11 | 2026-04-17 | 2026-03-31 | 2026-03-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-11 | 561.14 | 未披露 | 定期报告 | 2026-08-10 |
| 2026-08-11 | 466.57 | 0.03 |
更多>>
From April 1,2026 to June 30,2026
Issuance of preferred stock, net of costs and discount
Sale of equity through equity financing facilities, net of costs
Exercise of pre-funded warrants
Equity issued for payment of compensation and fees in lieu of cash
|
2026-06-30 |
| 2026-05-12 | 420.21 | 未披露 | 定期报告 | 2026-05-11 |
| 2026-05-04 | 398.33 | 未披露 | 定期报告 | 2026-04-17 |
| 2026-05-12 | 392.28 | 未披露 |
更多>>
From January 1, 2026 to March 31, 2026
Exercise of pre-funded warrants
|
2026-03-31 |
| 2026-03-31 | 392.28 | 未披露 | 定期报告 | 2026-03-30 |
| 2026-03-31 | 341.97 | 未披露 |
更多>>
From January 1, 2025 to December 31, 2025
Effect of reverse stock split
Stock dividend, net of offering costs
Sale of equity through equity financing facilities, net of issuance costs
Issuance of common stock upon exercise of common stock warrants
Shares issued in exchange for services
Issuance of stock upon vesting of restricted shares
|
2025-12-31 |
| 2025-11-13 | 307.04 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-12-31 | 289.67 | 未披露 |
更多>>
From July 1, 2025 to September 30, 2025
Shares issued to satisfy certain obligations
Issuance of common stock upon exercise of common stock warrants
Issuance of common stock upon exercise of restricted options
Stock dividend, net of offering costs
Sale of equity through equity financing facilities, net of costs
Effect of reverse stock split
|
2025-09-30 |
| 2025-08-05 | 264.04 | 未披露 |
更多>>
The stock dividend program will distribute a total of approximately 448,000 shares of additional shares of IMUNON common stock
|
2025-08-07 |
| 2025-08-05 | 219.24 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-08-05 | 212.19 | 未披露 |
更多>>
a 1-for-15 reverse split of the Company's common stock
|
2025-07-25 |
| 2025-07-23 | 3180.00 | 未披露 | 定期报告 | 2025-07-23 |
| 2025-07-22 | 3182.84 | 未披露 | 定期报告 | 2025-07-22 |
| 2025-06-09 | 2130.34 | 未披露 | 定期报告 | 2025-06-04 |
| 2025-05-30 | 2031.95 | 未披露 | 定期报告 | 2025-05-28 |
| 2025-06-09 | 1754.17 | 未披露 | 定期报告 | 2025-05-13 |
| 2025-05-12 | 1462.07 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Sale of equity through equity financing facilities, net of costs
|
2025-03-31 |
| 2025-02-27 | 1462.07 | 未披露 | 定期报告 | 2025-02-21 |
| 2024-11-07 | 1450.07 | 未披露 |
更多>>
From July 1, 2024 to September 30, 2024
Issuance of common stock upon exercise of restricted stock
Sale of equity through equity financing facilities, net of issuance costs
|
2024-09-30 |
| 2024-08-01 | 1440.09 | 未披露 |
更多>>
Common stock offered 5,000,000 shares by the company
|
2024-08-01 |
| 2024-05-13 | 940.09 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Issuance of common stock upon exercise of restricted options
|
2024-03-31 |
| 2024-03-28 | 939.98 | 未披露 |
更多>>
From January 1, 2023 to December 31, 2023
Issuance of common stock upon exercise of restricted options
Sale of equity through equity financing facilities
|
2023-12-31 |
| 2023-11-14 | 939.93 | 未披露 | 定期报告 | 2023-11-09 |
| 2023-11-14 | 936.79 | 未披露 |
更多>>
From July 1, 2023 to September 30, 2023
Issuance of common stock upon exercise of options
Sale of equity through equity financing facilities
|
2023-09-30 |
| 2023-08-10 | 936.79 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-08-10 | 925.20 | 未披露 |
更多>>
From April 1, 2023 to June 30, 2023
Sale of equity through equity financing facilities
|
2023-06-30 |
| 2023-05-11 | 909.70 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Issuance of common stock for restricted options
Sale of equity through equity financing facilities, net of costs
|
2023-03-31 |
| 2023-03-30 | 908.98 | 未披露 | 定期报告 | 2023-03-28 |
| 2023-03-30 | 743.62 | 未披露 |
更多>>
From January 1, 2022 to December 31, 2022
Issuance of common stock for restricted options
Sale of equity through equity financing facilities
Effect of reverse stock split
|
2022-12-31 |
| 2022-11-14 | 743.43 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-08-15 | 709.87 | 未披露 |
更多>>
From April 1, 2022 to June 30, 2022
Sale of equity through equity through registered direct offering
|
2022-06-30 |
| 2022-05-16 | 709.87 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-05-25 | 706.45 | 未披露 | 定期报告 | 2022-04-30 |
| 2022-04-08 | 709.88 | 未披露 |
更多>>
1.Common stock offered by 1,328,274 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 5,770,516 shares outstanding as of December 31, 2021.
|
2022-04-08 |
| 2022-05-25 | 577.05 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Net effect of reverse stock split
|
2022-03-31 |
| 2022-03-31 | 577.05 | 未披露 | 定期报告 | 2022-03-30 |
| 2022-02-28 | 580.00 | 未披露 |
更多>>
Celsion Corporation today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one (1) new Common Share for every fifteen (15) currently outstanding Common Shares. The new Common Shares will be effective for trading purposes as of the commencement of trading on Tuesday, March 1, 2022, and will trade under a new CUSIP number 15117N 602. The new number of outstanding common shares will be approximately 5.8 million shares.
|
2022-03-01 |
| 2021-08-12 | 8655.77 | 未披露 |
更多>>
From April 1, 2021 to June 30, 2021
Sale of equity through equity financing facilities
|
2021-06-30 |
| 2021-04-05 | 8655.77 | 未披露 |
更多>>
1.Common stock offered by the company 11,538,462 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 75,019,274 shares outstanding as of March 31, 2021.
|
2021-04-05 |
| 2021-05-14 | 7501.93 | 未披露 |
更多>>
From January 1, 2021 To March 31, 2021
Sale of equity through equity financing facilities
Shares issued upon exercise of common stock warrants, net of fees
Shares issued upon exercise of options to purchase common stock
|
2021-03-31 |
| 2021-03-19 | 7501.18 | 未披露 | 定期报告 | 2021-03-19 |
| 2021-03-19 | 7501.18 | 未披露 | 定期报告 | 2021-03-18 |
| 2021-01-26 | 6208.57 | 未披露 |
更多>>
1.Common stock offered by the company 25,925,925 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 36,159,780 shares outstanding as of September 30, 2020.
|
2021-01-26 |
| 2021-03-19 | 4070.10 | 未披露 |
更多>>
from January 1, 2020 to December 31, 2020
Sale of equity through equity financing facilities
Issuance of common stock upon exercise of options and vesting of stock awards
Issuance of common stock upon exercise of common stock warrants
Common stock issued to settle accrued bonuses
|
2020-12-31 |
| 2020-11-16 | 3741.77 | 未披露 | 定期报告 | 2020-11-13 |
| 2020-11-16 | 3615.98 | 未披露 |
更多>>
From July 1, 2020 to September 30, 2020
Sale of equity through financing facilities
Issuance of restricted stock
|
2020-09-30 |
| 2020-09-08 | 3344.29 | 未披露 | 定期报告 | 2020-09-06 |
| 2020-07-31 | 3323.24 | 未披露 | 定期报告 | 2020-07-30 |
| 2020-08-14 | 3322.94 | 未披露 |
更多>>
From April 1, 2020 to June 30, 2020
Sale of equity through financing facilities
Issuance of common stock upon exercise of options
|
2020-06-30 |
| 2020-06-24 | 3192.38 | 未披露 |
更多>>
1.Common stock offered 2,666,667 shares
2.The number of shares of our common stock outstanding is based on an aggregate of 29,257,101 shares of our common stock outstanding as of March 31, 2020
|
2020-06-24 |
| 2020-05-15 | 2925.71 | 未披露 |
更多>>
From January 1, 2020 to March 31, 2020
Sale of equity through equity financing facilities
Issuance of restricted stock in lieu of cash bonus
|
2020-03-31 |
| 2020-03-25 | 2925.71 | 未披露 | 定期报告 | 2020-03-24 |
| 2020-03-03 | 2782.72 | 未披露 |
更多>>
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par value $0.01 per share, pursuant to a registered direct offering.
|
2020-03-03 |
| 2020-03-25 | 2325.58 | 未披露 |
更多>>
From January 1, 2019 to December 31, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
|
2019-12-31 |
| 2019-11-14 | 2275.58 | 未披露 | 定期报告 | 2019-11-13 |
| 2019-11-14 | 2200.24 | 未披露 |
更多>>
from July 1, 2019 to September 30, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
|
2019-09-30 |
| 2019-08-14 | 2138.74 | 未披露 | 定期报告 | 2019-08-13 |
| 2019-08-14 | 2100.23 | 未披露 |
更多>>
From April 1, 2019 to June 30, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
|
2019-06-30 |
| 2019-05-15 | 2048.27 | 未披露 | 定期报告 | 2019-05-14 |
| 2019-05-15 | 1966.20 | 未披露 |
更多>>
from January 1, 2019 to March 31, 2019
Sale of equity through equity financing facilities
|
2019-03-31 |
| 2019-03-29 | 1956.20 | 未披露 | 定期报告 | 2019-03-28 |
| 2019-03-29 | 1883.18 | 未披露 |
更多>>
from January 1, 2018 to December 31, 2018
Sale of equity through ATM and common stock purchase agreement
Common stock issuance in exchange for cancellation of common stock warrants
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities
Issuance of restricted stock
|
2018-12-31 |
| 2018-11-14 | 1873.18 | 未披露 | 定期报告 | 2018-11-13 |
| 2018-11-14 | 1791.11 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-09-07 | 1791.11 | 未披露 | 定期报告 | 2018-09-06 |
| 2018-09-07 | 1780.66 | 未披露 | 定期报告 | 2018-09-05 |
| 2018-08-14 | 1774.63 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-11 | 1774.00 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-30 | 1774.00 | 未披露 | 定期报告 | 2018-03-20 |
| 2018-03-27 | 1727.70 | 未披露 |
更多>>
from January 1, 2016 to December 31, 2017
Registered direct common stock offerings
Conversion of common stock warrants
Issuance of restricted stock
Issuance of common stock out of treasury
|
2017-12-31 |
| 2017-11-14 | 1606.23 | 未披露 |
更多>>
On October 4, 2017, the Company entered into letter agreements (the “Exercise Agreements”) with the holders of the Series AAA and Series BBB Warrants issued in the July 6, 2017 Common Stock Offering (the “Exercising Holders”). The Exercise Agreements amended the Series AAA Warrants to permit their immediate exercise. Prior to the execution of the Exercise Agreements, the Series AAA Warrants were not exercisable until January 11, 2018. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would exercise all of their Existing Warrants with respect to 4,665,000 shares of Common Stock underlying such Existing Warrants. The Series AAA Warrants and Series BBB Warrants were exercised at a price of $2.07 per share and $4.75 per share, respectively, which were their respective original exercise prices.
On October 27, 2017, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc. (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 2,640,000 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants to purchase an aggregate of 1,320,000 shares of Common Stock. Each share of Common Stock is being sold together with 0.5 warrants (the “Investor Warrants”), each whole Investor Warrant being exercisable for one share of Common Stock, at an offering price of $2.50 per share and related Investor Warrants.
|
2017-11-13 |
| 2017-11-14 | 835.47 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-14 | 835.13 | 未披露 |
更多>>
On July 6, 2017, the Company entered into a securities purchase agreement with several investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering, an aggregate of 2,050,000 shares of common stock of the Company at an offering price of $2.07 per share for gross proceeds of $4,243,500 before the deduction of the placement agent fee and offering expenses.
|
2017-08-11 |
| 2017-08-14 | 591.42 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-06-06 | 396.19 | 未披露 |
更多>>
For the three and six month periods ended June 30, 2016, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1,395,290 shares.
|
2017-05-31 |
| 2017-05-26 | 410.00 | 未披露 |
更多>>
The Company authorized and approved a fourteen-for-one stock split of the Company’s issued Common Stock. Such additional shares of Common Stock are expected to be distributed on or about May 30, 2017.
|
2017-05-30 |
| 2017-05-12 | 5698.24 | 未披露 | 定期报告 | 2017-05-10 |
| 2017-04-05 | 5546.65 | 未披露 | 定期报告 | 2017-03-23 |
| 2017-04-04 | 5536.65 | 未披露 | 定期报告 | 2017-03-20 |
| 2017-03-24 | 3122.17 | 未披露 |
更多>>
from January 1, 2016 to December 31, 2016
Registered Direct common stock offerings
Conversion of common stock warrants
Issuance of restricted stock
Issuance of common stock out of treasury
|
2016-12-31 |
| 2016-11-10 | 2607.88 | 未披露 | 定期报告 | 2016-11-09 |
| 2016-11-10 | 2606.06 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-15 | 2581.06 | 未披露 | 定期报告 | 2016-08-12 |
| 2016-07-08 | 2579.56 | 未披露 | 定期报告 | 2016-07-07 |
| 2016-08-15 | 2578.06 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-16 | 2343.68 | 未披露 | 定期报告 | 2016-05-13 |
| 2016-05-16 | 2342.47 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-30 | 2342.47 | 未披露 | 定期报告 | 2016-03-29 |
| 2016-03-30 | 2331.93 | 未披露 |
更多>>
from January 1, 2015 to December 31, 2015
Registered Direct and ATM common stock offerings
Issuance of restricted stock
Issuance of common stock out of treasury
|
2015-12-31 |
| 2015-11-05 | 2323.76 | 未披露 | 定期报告 | 2015-11-04 |
| 2015-08-10 | 2302.80 | 未披露 | 定期报告 | 2015-08-07 |
| 2015-06-19 | 2300.52 | 未披露 | 定期报告 | 2015-06-18 |
| 2015-04-30 | 2000.52 | 未披露 | 定期报告 | 2015-04-24 |
| 2015-03-12 | 1998.47 | 未披露 | 定期报告 | 2015-03-11 |
| 2014-11-10 | 1997.65 | 未披露 | 定期报告 | 2014-11-10 |
| 2014-03-13 | 1721.55 | 未披露 | 定期报告 | 2014-03-12 |
| 2013-06-07 | 5268.99 | 未披露 | 定期报告 | 2013-05-24 |
| 2013-05-09 | 5161.29 | 未披露 | 定期报告 | 2013-05-08 |
| 2013-03-18 | 5083.29 | 未披露 | 定期报告 | 2013-03-15 |
| 2011-08-09 | 2628.25 | 未披露 | 定期报告 | 2011-08-08 |
| 2011-08-09 | 1970.51 | 0.09 |
更多>>
from dec 31 2010 to jun 30 2011
Conversion of 8% Series A Redeemable, Convertible Preferred Stock
Shares issued under CEFF, net of issuance costs
Shares issued under private placement common stock offering on
June 2, 2011
Issuance of restricted stock upon vesting
Issuance of common stock out of treasury for 401(k) plan matching contribution
|
2011-06-30 |
| 2011-05-12 | 1491.83 | 未披露 | 定期报告 | 2011-05-11 |
| 2011-05-12 | 1387.36 | 0.45 |
更多>>
Conversion of 8% Series A Redeemable, Convertible Preferred Stock
Shares issued under CEFF, net of issuance costs
Issuance of restricted stock upon vesting
Issuance of common stock out of treasury for 401(k) plan matching contribution
|
2011-03-31 |
| 2003-12-29 | 14791.52 | 未披露 | 定期报告 | 2003-12-15 |
| 2002-12-30 | 9649.26 | 未披露 | 定期报告 | 2002-12-26 |
| 2002-12-30 | 9241.76 | 0.27 |
更多>>
from September 30, 2001 to September 30, 2002
Sale of preferred and common stock
Issuance of warrants/options and common stock for payment of expenses
Conversion of shares of Series A 10% convertible, preferred stock plus accrued dividends
Conversion of shares of Series B 8% convertible, preferred stock plus accrued dividends
Exercise of common stock warrants and options
Preferred stock dividend
|
2002-09-30 |
| 2001-12-28 | 8529.22 | 未披露 | 定期报告 | 2001-12-20 |
| 2001-12-28 | 7687.68 | 0.11 |
更多>>
from September 30, 2000 to September 30, 2001
Sale of common stock
Issuance of shares of common stock as payment for operating expenses
Conversion of shares of Series A 10% convertible, preferred stock plus accrued dividend
Exercise of preferred stock warrants
Preferred stock dividend
|
2001-09-30 |
| 2000-12-28 | 6448.76 | 未披露 | 定期报告 | 2000-11-30 |
| 2000-12-28 | 6437.21 | 0.52 |
更多>>
from September 30, 1999 to September 30, 2000
Sale of common stock
Issuance of 753,025 shares of common stock as payment of indebtedness and expenses
Preferred stock dividend
Issuance of 4,853 shares of Series A10% convertible preferred stock (net of issuance costs)
|
2000-09-30 |
From April 1,2026 to June 30,2026
Issuance of preferred stock, net of costs and discount
Sale of equity through equity financing facilities, net of costs
Exercise of pre-funded warrants
Equity issued for payment of compensation and fees in lieu of cash
From January 1, 2026 to March 31, 2026
Exercise of pre-funded warrants
From January 1, 2025 to December 31, 2025
Effect of reverse stock split
Stock dividend, net of offering costs
Sale of equity through equity financing facilities, net of issuance costs
Issuance of common stock upon exercise of common stock warrants
Shares issued in exchange for services
Issuance of stock upon vesting of restricted shares
From July 1, 2025 to September 30, 2025
Shares issued to satisfy certain obligations
Issuance of common stock upon exercise of common stock warrants
Issuance of common stock upon exercise of restricted options
Stock dividend, net of offering costs
Sale of equity through equity financing facilities, net of costs
Effect of reverse stock split
The stock dividend program will distribute a total of approximately 448,000 shares of additional shares of IMUNON common stock
a 1-for-15 reverse split of the Company's common stock
From January 1, 2025 to March 31, 2025
Sale of equity through equity financing facilities, net of costs
From July 1, 2024 to September 30, 2024
Issuance of common stock upon exercise of restricted stock
Sale of equity through equity financing facilities, net of issuance costs
Common stock offered 5,000,000 shares by the company
From January 1, 2024 to March 31, 2024
Issuance of common stock upon exercise of restricted options
From January 1, 2023 to December 31, 2023
Issuance of common stock upon exercise of restricted options
Sale of equity through equity financing facilities
From July 1, 2023 to September 30, 2023
Issuance of common stock upon exercise of options
Sale of equity through equity financing facilities
From April 1, 2023 to June 30, 2023
Sale of equity through equity financing facilities
From January 1, 2023 to March 31, 2023
Issuance of common stock for restricted options
Sale of equity through equity financing facilities, net of costs
From January 1, 2022 to December 31, 2022
Issuance of common stock for restricted options
Sale of equity through equity financing facilities
Effect of reverse stock split
From April 1, 2022 to June 30, 2022
Sale of equity through equity through registered direct offering
1.Common stock offered by 1,328,274 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 5,770,516 shares outstanding as of December 31, 2021.
From January 1, 2022 to March 31, 2022
Net effect of reverse stock split
Celsion Corporation today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one (1) new Common Share for every fifteen (15) currently outstanding Common Shares. The new Common Shares will be effective for trading purposes as of the commencement of trading on Tuesday, March 1, 2022, and will trade under a new CUSIP number 15117N 602. The new number of outstanding common shares will be approximately 5.8 million shares.
From April 1, 2021 to June 30, 2021
Sale of equity through equity financing facilities
1.Common stock offered by the company 11,538,462 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 75,019,274 shares outstanding as of March 31, 2021.
From January 1, 2021 To March 31, 2021
Sale of equity through equity financing facilities
Shares issued upon exercise of common stock warrants, net of fees
Shares issued upon exercise of options to purchase common stock
1.Common stock offered by the company 25,925,925 shares.
2.The number of shares of common stock shown above to be outstanding immediately before and after this offering is based on 36,159,780 shares outstanding as of September 30, 2020.
from January 1, 2020 to December 31, 2020
Sale of equity through equity financing facilities
Issuance of common stock upon exercise of options and vesting of stock awards
Issuance of common stock upon exercise of common stock warrants
Common stock issued to settle accrued bonuses
From July 1, 2020 to September 30, 2020
Sale of equity through financing facilities
Issuance of restricted stock
From April 1, 2020 to June 30, 2020
Sale of equity through financing facilities
Issuance of common stock upon exercise of options
1.Common stock offered 2,666,667 shares
2.The number of shares of our common stock outstanding is based on an aggregate of 29,257,101 shares of our common stock outstanding as of March 31, 2020
From January 1, 2020 to March 31, 2020
Sale of equity through equity financing facilities
Issuance of restricted stock in lieu of cash bonus
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par value $0.01 per share, pursuant to a registered direct offering.
From January 1, 2019 to December 31, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
from July 1, 2019 to September 30, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
From April 1, 2019 to June 30, 2019
Sale of equity through equity financing facilities
Issuance of restricted stock
from January 1, 2019 to March 31, 2019
Sale of equity through equity financing facilities
from January 1, 2018 to December 31, 2018
Sale of equity through ATM and common stock purchase agreement
Common stock issuance in exchange for cancellation of common stock warrants
Common stock and warrants to purchase common stock issued in connection with equity and debt facilities
Issuance of restricted stock
from January 1, 2016 to December 31, 2017
Registered direct common stock offerings
Conversion of common stock warrants
Issuance of restricted stock
Issuance of common stock out of treasury
On October 4, 2017, the Company entered into letter agreements (the “Exercise Agreements”) with the holders of the Series AAA and Series BBB Warrants issued in the July 6, 2017 Common Stock Offering (the “Exercising Holders”). The Exercise Agreements amended the Series AAA Warrants to permit their immediate exercise. Prior to the execution of the Exercise Agreements, the Series AAA Warrants were not exercisable until January 11, 2018. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would exercise all of their Existing Warrants with respect to 4,665,000 shares of Common Stock underlying such Existing Warrants. The Series AAA Warrants and Series BBB Warrants were exercised at a price of $2.07 per share and $4.75 per share, respectively, which were their respective original exercise prices.
On October 27, 2017, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc. (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 2,640,000 shares (the “Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”), and warrants to purchase an aggregate of 1,320,000 shares of Common Stock. Each share of Common Stock is being sold together with 0.5 warrants (the “Investor Warrants”), each whole Investor Warrant being exercisable for one share of Common Stock, at an offering price of $2.50 per share and related Investor Warrants.
On July 6, 2017, the Company entered into a securities purchase agreement with several investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering, an aggregate of 2,050,000 shares of common stock of the Company at an offering price of $2.07 per share for gross proceeds of $4,243,500 before the deduction of the placement agent fee and offering expenses.
For the three and six month periods ended June 30, 2016, the total number of shares of common stock issuable upon exercise of warrants and equity awards was 1,395,290 shares.
The Company authorized and approved a fourteen-for-one stock split of the Company’s issued Common Stock. Such additional shares of Common Stock are expected to be distributed on or about May 30, 2017.
from January 1, 2016 to December 31, 2016
Registered Direct common stock offerings
Conversion of common stock warrants
Issuance of restricted stock
Issuance of common stock out of treasury
from January 1, 2015 to December 31, 2015
Registered Direct and ATM common stock offerings
Issuance of restricted stock
Issuance of common stock out of treasury
from dec 31 2010 to jun 30 2011
Conversion of 8% Series A Redeemable, Convertible Preferred Stock
Shares issued under CEFF, net of issuance costs
Shares issued under private placement common stock offering on
June 2, 2011
Issuance of restricted stock upon vesting
Issuance of common stock out of treasury for 401(k) plan matching contribution
Conversion of 8% Series A Redeemable, Convertible Preferred Stock
Shares issued under CEFF, net of issuance costs
Issuance of restricted stock upon vesting
Issuance of common stock out of treasury for 401(k) plan matching contribution
from September 30, 2001 to September 30, 2002
Sale of preferred and common stock
Issuance of warrants/options and common stock for payment of expenses
Conversion of shares of Series A 10% convertible, preferred stock plus accrued dividends
Conversion of shares of Series B 8% convertible, preferred stock plus accrued dividends
Exercise of common stock warrants and options
Preferred stock dividend
from September 30, 2000 to September 30, 2001
Sale of common stock
Issuance of shares of common stock as payment for operating expenses
Conversion of shares of Series A 10% convertible, preferred stock plus accrued dividend
Exercise of preferred stock warrants
Preferred stock dividend
from September 30, 1999 to September 30, 2000
Sale of common stock
Issuance of 753,025 shares of common stock as payment of indebtedness and expenses
Preferred stock dividend
Issuance of 4,853 shares of Series A10% convertible preferred stock (net of issuance costs)